Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler (GRAFD Trial)

NCT04502823 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT04502823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04502823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler (GRAFD Trial)
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Not applicable
Overall status
Completed
Start date
September 21, 2020
Completion date
December 18, 2022
Enrollment
1,088 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

fetal growth retardation